Joan Kutcher

Joan Kutcher

Subscribe to all posts by Joan Kutcher

What is the Prognosis for Health Care Issues in the Next Congress?

Joan Kutcher and Gary Heimberg delivered remarks during Covington’s post-election conference call with clients on November 8, 2018 on health care and drug pricing.  The health care segment follows:  The Affordable Care Act has been an issue in every election since it passed in 2010.  This election was the first time the Democrats could fully … Continue Reading

Level-setting the President’s Budget Blueprint and Rx Pricing: Putting the Process and Substance in Context

Today, the President will submit the Administration’s Fiscal Year 2019 budget blueprint to Congress.  The document will set in motion an annual process to analyze the substance, business implications and prospects for various proposals.  Draft documents have already begun to circulate that suggest that both the budget and a forthcoming addendum would, if enacted, have … Continue Reading

Trump Order Relating to Affordable Care Act

On January 20, 2017, President Donald J. Trump signed an Executive Order instructing federal agencies to work to “minimize the unwarranted economic and regulatory burdens” of the Affordable Care Act (“ACA”), and to increase the flexibility provided to States to run healthcare programs. While the Executive Order itself does not change any regulation or specific … Continue Reading

Trump and Health Care

It is safe to observe that modifying or repealing the Affordable Care Act (aka as Obamacare) will be the top health care-related priority of the Trump Administration. Trump spoke about repeal and replace often — he even called for a special session of Congress to repeal it — and while it was not among his … Continue Reading

The Dynamic Political and Public Policy Landscape in DC on Pharmaceutical Issues

The post-election period — from the lame duck congressional session to the first 100 days and beyond of a new Administration and Congress — is expected to be a time of extraordinary, if not unprecedented, public policy debate on issues that impact pharmaceutical/life sciences companies and interest groups. These issues present both significant threats and … Continue Reading
LexBlog